Omada Health
Buying intent
129 tracked signals | Top 15 topics are below | Support and Marketing are carrying most of it.
Attention by team
LinkedIn activity, by teamWhere Omada Health's own people are actually spending their attention, by team, by topic. Bands run Low to High against the busiest pairing on this page, and each cell also shows how much of that team's own activity it represents.
Topics being researched
30-day windowEvery tracked topic, ranked by volume, not by our guess at what matters. Confidence is the classifier's own certainty that a signal belongs where we've filed it.
18d ago
11d ago
18d ago
11d ago
13d ago
18d ago
18d ago
2d ago
13d ago
18d ago
18d ago
21d ago
19d ago
18d ago
2d ago
Need intent for a specific topic or industry?
We track the full taxonomy across every account in the graph — including themes not shown on this page.
Who's active at Omada Health
verified title on fileTitles, seniority and topic straight from each person's own activity, with a LinkedIn link so you can check any of them yourself.
See everyone, not just the first 10
24 people across every department at Omada Health, plus a LinkedIn profile link for each.
Primary products / business lines
LinkedIn company profileFor 15 years, Omada Health has been in the corner of millions of Americans managing chronic conditions. We help our members between doctor visits, providing virtual care that adapts to real life. We partner with employers, health plans, pharmacy benefit managers, and government agencies to support their populations across common chronic conditions — from prediabetes, diabetes, and hypertension to
New capability sought
Employee posts (LinkedIn)Channel Enablement; Physical Therapy; AI Agent Security; AI Agent Software; Agentic AI System; Carve-Out; Chronic condition management; Healthcare Operations
Top accounts researching Omada Health
names withheld on the public pageThese are companies whose own people brought up Omada Health unprompted, not accounts we guessed might be interested. We can't yet tell an implementation partner from a genuine buyer here, names unlock along with the buyer profile below.
- Account withheldSalesforce6 contacts
- Account withheldNozomi - Digital Health Product Studio1 contacts
- Account withheldUSI Insurance Services1 contacts
- Account withheldePlus inc.1 contacts
- Account withheldMedicines Control Authority of Zimbabwe1 contacts
- Account withheldAmazon Web Services1 contacts
- Account withheldMaven Clinic1 contacts
- Account withheldTPN.health1 contacts
- Account withheldKilo1 contacts
- Account withheldONL Therapeutics1 contacts
- Account withheldRoyal Air Force (RAF)1 contacts
- Account withheldTeKnowledge1 contacts
- Account withheldFocusCFO®1 contacts
- Account withheldINLIFE Pharma Private Limited1 contacts
- Account withheldU.S. Department of Veterans Affairs1 contacts
Buyer profile
company size · seniorityCompany size and how senior the people involved are, the two things that decide whether this is a real deal. Competitor overlap isn't computed yet for this account.
Buying committee functions
Employee job titles (LinkedIn)Leadership — 3 people; Customer Success — 3 people; Marketing — 3 people; Operations — 2 people; Engineering — 2 people; Sales — 2 people
What's been said
public posts mentioning Omada HealthUp to 9 public excerpts naming Omada Health from the past 365 days, across LinkedIn, Reddit, X, YouTube and other public sources.
Big news: Omada Health will participate in Lilly’s Employer Connect program, adding another way to offer employers our GLP-1 Care Track alongside our existing pharmacy benefit manager and cash‑pay channels. That means more ways for employers to offer GLP‑1 medications with coordinated virtual care and lifestyle support. Omada also surveyed more than 3,000 people using or having used GLP‑1s and found that access alone isn’t enough—patients want help with nutrition, exercise, and what happens after the prescription. Proud to see Omada expanding responsible GLP‑1 access and support for both employers and members. Read more in the press release: https://lnkd.in/grk2qCeR
May 2026The benefit design conversation has shifted for employers. It’s not IF we should cover GLP-1s, but HOW. Thursday we announced that Omada Health will be an independent administrator in Eli Lilly and Company 's Employer Connect program, adding another way for employers to pair GLP-1 access with our GLP-1 Care Track for coordinated, virtual lifestyle support before, during, and after medication. Employers have options now. Between PBM solutions, Lilly’s Employer Connect, and Omada’s own GLP‑1 Flex Care, there’s a full menu of GLP‑1 support pathways to fit the needs of their population and budget—while pairing medication with behavior change, muscle preservation, and cardiometabolic risk reduction through Omada’s program. While we’ve been building this menu out, we’ve also been listening to patients. What we heard: for many, access is no longer the bottleneck. Support is. In a survey of over 3,000 GLP-1 patients from Omada, we found patients still face stigma, support gaps, and rising out‑of‑pocket costs that threaten continuity of care. Learn more: https://buff.ly/gkOng4a
May 2026If your employees are on GLP-1s and you're only tracking pounds lost, you're measuring the wrong thing. Up to 40% of GLP-1 weight loss can come from lean mass—not fat. That's muscle your members need for strength, metabolism, and long-term health. It's also a direct threat to the durability of your GLP-1 investment. Omada Health recently published a 12-week study of 245 adults on GLP-1s. Members in Omada's GLP-1 Care Track, on average, lost 1.8x more total weight and 2.1x more body fat while preserving muscle mass compared to a control group. They also reported meaningful improvements in mental health, physical functioning, and confidence in their ability to sustain weight loss. For employers and health plans, the implication is clear: the ROI of GLP-1s depends on the quality of the weight loss, not just the quantity. Programs that pair medication with strength-focused behavioral support protect the outcomes you're paying for—and the people behind them. Read the full analysis: https://lnkd.in/gWJdxe3b
Apr 2026Budget pressure / cost-cutting signal
Earnings call; SEC filingsCost of Revenue: 2,40,48,000 USD